How AZ and Amgen's Tezspire respiratory data ups the ‘level of ambition' in immunology [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
What do you get when you combine the efforts of one of the world's leading respiratory drugmakers with a global pioneer in biological medicines? You get a next-gen treatment like Tezspire, which according to pivotal results revealed this month, could become an important new therapy for an underserved respiratory condition. Co-developed by biopharma giants AstraZeneca and Amgen, and approved in 2021 for severe asthma, Tezspire raked in combined sales of $1.2 billion for the full year 2024. Now, late-stage data in the respiratory condition chronic rhinosinusitis with nasal polyps, or CRSwNP, showed that the drug reduces the need for surgery by a startling 98% and the use of corticosteroids by 88%. The results underscore a growing conver
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up [CNBC]CNBC
- Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions' [Yahoo! Finance]Yahoo! Finance
- IgniteData to deploy EHR-to-EDC automation tool in Phase III trial at MSK [Yahoo! Finance]Yahoo! Finance
- ??AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trialBusiness Wire
- IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 4/1/25 - Form 6-K
- 3/31/25 - Form 6-K
- 3/31/25 - Form 6-K
- AZN's page on the SEC website